Skip to main content
Signal8

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

$GILDPress releaseJun 23, 2026, 7:45 AM ETRead the release

The European Commission approved Gilead's Trodelvy as a first-line monotherapy for metastatic triple-negative breast cancer patients who are not candidates for PD-(L)1 inhibitor therapy. This makes Trodelvy the first antibody-drug conjugate approved for this specific patient population in the European Union. The authorization was supported by data from the Phase 3 ASCENT-03 study, where Trodelvy demonstrated a 38% reduction in the risk of disease progression or death compared to standard chemotherapy.

Key figures

Phase of trial
Phase 3
Risk reduction
38%
Patients treated since 2020
75000

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.